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What is the optimal regimen for vitamin D? The past 30 years mineral metabolism. This encompasses the metabolic
have seen substantial advances in our understanding of the and structural aspects of skeletal function, the physiolog-
pathogenesis of the mineral, hormonal and skeletal disorders ical concentrations of the major mineral ions, the mainte-that comprise renal osteodystrophy. The introduction of calci-
nance of appropriate circulating concentrations of thetriol and alfacalcidol as treatments for this disorder in the early
1970s represented an enormous step forward in clinical practice, major calcium-regulating hormones (parathyroid hor-
but unfortunately, the subsequent refinement of these therapies mone [PTH] and calcitriol), and finally, the prevention
still leaves us well short of the ideal: hyperphosphatemia and of abnormal parathyroid gland hyperplasia. Althoughhypercalcemia induced by the vitamin D metabolites, and fail-
fairly straightforward in concept, these objectives haveure to control parathyroid hyperplasia, all remain problematic.
nevertheless proved extremely elusive, and as a resultNovel pulsed regimens using alfacalcidol and calcitriol, while
clearly effective, have not fulfilled initial high expectations of the field has been associated with the development of a
superiority in the context of comparative studies. New vitamin D range of clinical strategies that, although in many ways
metabolites, some of which have exhibited desirable selectivity in
effective, are far from perfect. In parallel with this hasexperimental settings with reduced tendency to raise phosphate
been an intense basic and clinical scientific effort aimedand/or calcium while maintaining good control of the parathy-
roid glands, are now being evaluated. Of these, 22-oxacalcitriol, at the better understanding of the underlying pathophys-
paricalcitol (19 nor-1,25 dihydroxyvitamin D2) and doxercalcif- iology of renal osteodystrophy. The main focus has been
erol (1a-hydroxyvitamin D2) have all shown high efficacy when on 1) the skeletal abnormalities; 2) the abnormalitiescompared with placebo, but so also did alfacalcidol and cal-
of calcium and phosphorus metabolism; 3) vitamin Dcitriol in similar studies in the 1970s and 1980s. The results of
randomized studies comparing the new vitamin D metabolites bioactivation and action in relation to renal disease; and
with current standard therapy (alfacalcidol or calcitriol) are 4) parathyroid gland function and the biology of parathy-
either not yet available or show uncertain benefits in relation to roid hormone.hypercalcemia, hyperphosphatemia and hyperparathyroidism.
The impact of these new metabolites on the increasing preva-
lence of low turnover bone disease is unknown, although exper-
RELEVANT PATHOPHYSIOLOGYimentally there is evidence of potentially important differences
at the level of the skeleton. Mineral ions and hormones
Changes to mineral ion concentrations and the calcium
regulating hormones as renal function declines are drivenThis review will approach the issue of optimal vitamin
principally by the combination of increasing impairmentD treatment for patients with renal failure by consider-
of the kidneys’ ability to synthesize calcitriol, coupled withing, in order, the treatment objectives, relevant patho-
progressive impairment of phosphate excretory capacity.physiology, the status and efficacy of current strategies,
Both of these abnormalities lead directly and indirectlyand finally the status and prospects for very recently
to increased parathyroid stimulation with resulting in-developed and emerging strategies. Of necessity the re-
creases in the synthesis and secretion of PTH. The ensuingview will therefore consider vitamin D metabolites that
secondary hyperparathyroidism promotes phosphaturiahave been in clinical use for many years, as well as those
that are only just beginning to enter the clinical arena. and increased activity of the renal 25-hydroxyvitamin D
1a-hydroxylase, thereby tending to normalize plasma con-
centrations of, respectively, phosphate and calcitriol [1].TREATMENT OBJECTIVES
The price paid is significant, however, in that increased
At a basic level, treatment objectives are quite easy circulating PTH concentrations drive a range of unwanted
to define and are given in Table 1. In essence, treatment
effects on target organs, in particular the skeleton [2].aims to achieve and maintain a state of normal bone and
Furthermore, the unremitting parathyroid stimulation is
associated with a sustained increase in mitotic activity
with the development of parathyroid gland hyperplasia 1999 by the International Society of Nephrology
S-59
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Table 1. Therapeutic objectives
Maintenance of normal skeletal function
Metabolism
Bone turnover
Mechanical integrity
Maintenance of normal ECF mineral ion concentrations
Maintenance of appropriate parathyroid suppression
Optimal PTH
Prevention of hyperplasia
Fig. 2. Stimulatory inputs to parathyroid activity. Those depicted by
the thick arrows are dependent directly or indirectly on the state of
calcitriol sufficiency, and are therefore totally or partially correctable
by calcitriol therapy. Abbreviations are: Ca, extracellular calcium concen-
tration; CaR, extracellular calcium receptor; VDR, vitamin D receptor.
nous calcitriol or related agents that act via the vitamin D
receptor. The mechanisms whereby these major control-
lers influence the parathyroids has been the subject of
intense study and is reviewed elsewhere in this supple-
ment. Suffice to say, however, that calcitriol acts directlyFig. 1. Control of parathyroid activity by calcium, phosphate and
calcitriol. In health, each of these modulators forms a negative feed- on the parathyroid glands to suppress PTH gene tran-
back loop with PTH. In end stage renal disease the PTH–phosphate scription and also parathyroid cell mitotic activity. In
loop changes to positive feedback. Abbreviations are: PTH, parathyroid
contrast, calcium and phosphate both regulate PTHhormone; Ca, calcium; Pi, inorganic phosphate.
synthesis by post-transcriptional effects on preproPTH
mRNA. All three have powerful effects on parathyroid
cell mitotic activity. Calcium in addition exerts minute
[3, 4]. This latter development is of great clinical impor- to minute modulation of parathyroid hormone release
tance. It is becoming increasingly clear that the kinetics via the extracellular calcium receptor.
of parathyroid cell division and apoptosis are such that,
Bonealthough hyperplasia can develop quite quickly, reversal
by apoptosis is so slow as to be almost irrelevant clinically Hyperparathyroid bone disease was much the most
[4, 5]. The dynamic interactions between the parathy- common lesion seen in the early years of maintenance
roids and the three principal modulators of parathyroid dialysis treatment and is characterized by increased activ-
activity, namely, calcium, phosphate and calcitriol, are ity of both osteoblasts and osteoclasts [6, 7]. Bone forma-
illustrated in Fig. 1. Note that in health each of the three tion and resorption rates are thus increased and this may
modulators is part of a negative feedback loop, thereby be recognized histologically by the presence of excessive
favoring a damping function and maintenance of an ap- amounts of osteoid with high mineralization activity (re-
propriate steady state. In contrast, the presence of end- flecting accelerated bone formation), and also by in-
creased numbers of osteoclasts seen to be resorbing bonestage renal disease introduces a positive feedback loop.
In this instance the normal action of PTH to promote actively (reflecting increased bone resorptive rates).
The last decade has, however, seen the emergence ofphosphaturia and thereby decrease serum phosphate is
sabotaged by the renal failure with the result that PTH strikingly different bone lesions. In particular, adynamic
bone (also designated aplastic bone disease or the ady-serves to elevate serum phosphate by acceleration of
phosphorus efflux from the skeleton. In addition to its namic bone disorder) is seen in increasing numbers of
patients. This was first recognized in association withthree main modulators, parathyroid cell activity is also
influenced by a considerable number of other processes, aluminum intoxication and characterized by striking re-
duction of cellular activity with deposition of aluminummany of which are themselves a reflection of the lack of
hormonal calcitriol synthesized by the kidney (Fig. 2). at the mineralization front [8]. Subsequently, the effec-
tive removal of aluminum from the environment of theAll of these are therefore potentially amenable to partial
or complete correction during administration of exoge- hemodialysis patient has not, as would have been ex-
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pected, led to the disappearance of the adynamic bone sustained clinical responses often seen (Fig. 3). Also
counterproductive in this setting are the potent calcemiclesion but instead has been temporally associated with
and phosphatemic actions of calcitriol and alfacalcidol,a progressive increase in its prevalence [7]. The explana-
both of which substantially increase the intestinal ab-tion for this is far from clear, but important associations
sorption of both calcium and phosphorus. The develop-include advanced age, the use of large amounts of cal-
ment of hypercalcemia frequently limits the dose thatcium containing phosphorus binders, high calcium dialy-
can be used and the tendency to hyperphosphatemiasate, coexistent diabetes mellitus and previous glucocor-
is clearly disadvantageous in a clinical scenario whereticoid therapy. These demographic factors have been
hyperphosphatemia is already a significant problem.increasingly in evidence over the past 10–15 years. Ady-
As a result of these limitations attempts have beennamic bone is usually, although not always, associated
made over the past 10 years to devise alternative sched-with relatively low PTH, in or just above the normal
ules of administration that might prove more efficacious,range or even subnormal in certain patients. In between
in particular with the aim of selectively targeting thethese two extremes lies a group of patients who manifest
parathyroid glands for suppression without at the samenormal bone turnover, and it is this that currently repre-
time fueling hypercalcemia and hyperphosphatemia viasents the best skeletal therapeutic target. In this group
the intestine and bone. Novel and somewhat unphysio-it is usual to see moderately elevated PTH concentration
logical regimens for the administration of calcitriol andat 2–4 times the upper limit of normal on an intact PTH
alfacalcidol were reported, initially by Madsen et al [14](1–84) assay, typically 100–200 pg/ml.
and subsequently by Slatopolsky et al [15], both of whom
studied the effect of intermittent intravenous dosing with
CURRENT STRATEGIES calcitriol. These and subsequent studies appeared to
show excellent clinical outcomes from intravenous dos-The optimal use of vitamin D therapies cannot be
ing [16, 17] as did some reports of intermittent pulsed oralconsidered in isolation, invariably being part of a broader
dosing [18, 19]. Unfortunately, a dispassionate review ofattack on the derangements of uremia. Of crucial impor-
the literature reveals that, although many studies havetance is the control of hyperphosphatemia; this remains
raised the possibility of enhanced efficacy of these newdifficult and unsatisfactory for large numbers of patients
regimens, formal comparisons between intravenous or[9, 10]. Currently available dietary phosphate binders all
pulsed oral therapies on the one hand, and conventionalsuffer from relative lack of efficacy and weak action and
daily oral therapies on the other, have revealed little ormost have potential or real toxicity. As a result many
no clinical benefit either way [20, 21]. Nor have studiespatients with advanced renal failure and those on dialysis
comparing alfacalcidol with calcitriol shown any impor-are maintained in a state of moderate or severe hyper-
tant differences between the two, perhaps not surprisingphosphatemia, with continued phosphate mediated drive
given that alfacalcidol is no more than a prodrug forto PTH synthesis and parathyroid cell hyperplasia [11].
calcitriol. The results of the first comparative studiesThis is of great importance in relation to calcitriol and
published over 2 decades ago still hold true [22].other vitamin D therapies; it has become increasingly
clear that poor phosphate control is a powerful predictor
of unsatisfactory outcomes to vitamin D therapies. The NEW VITAMIN D METABOLITES
first clinical use of 1a-hydroxylated vitamin D metabo- The realization that vitamin D metabolites exhibit a
lites was in 1971 when Brickman et al showed effective range of biological actions that extend far beyond those
elevation of calcium and reduction of PTH following the connected with bone and mineral metabolism, in many
use of calcitriol [12]. Similar results with alfacalcidol were cases associated with powerful anti-proliferative and pro-
reported shortly thereafter [13] and these two agents differentiation effects, has raised the possibility that
quickly became established as the standard form of vita- these agents may be used in malignancy and other dis-
min D therapy in patients with renal disease, as well as eases associated with excessive cell turnover [23]. Clini-
in some other vitamin D resistant syndromes. The main cal and basic scientists, and the pharmaceutical industry,
problem with these treatments has been their frequent have together mounted an intensive search for structur-
failure to sustain the favorable early responses of the ally modified vitamin D metabolites that may selectively
parathyroids and it is now clear that early suppression act upon some target tissues at the expense of others.
of PTH is often followed by subsequent breakthrough, In the field of cancer, a desirable profile would be a
increasing parathyroid hyperplasia and eventual para- vitamin D metabolite able to act via the vitamin D recep-
thyroidectomy in some patients. We have found that tor on the relevant malignant cells, but not acting to the
the enhanced parathyroid suppressibility by calcium that same degree on traditional calcemic target tissues. By
initially follows calcitriol therapy is not sustained, analogy other agents might confer the major advantage
of enabling effective parathyroid suppression with les-thereby providing a functional correlate with the poorly
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Fig. 3. Effect of calcitriol therapy on parathy-
roid sensitivity to extracellular calcium. Pa-
tients were given pulse oral calcitriol. Although
after one month a marked increase in parathy-
roid suppression was seen, this was not fully
sustained when re-tested after six months of
calcitriol therapy. Abbreviations are: PTH,
parathyroid hormone; Ca11, increment or
decrement of extracellular calcium ion con-
centration.
sened or absent risk of hypercalcemia and of hyperphos- results suggested that paricalcitol should bring substan-
tial clinical benefits.phatemia. A number of these agents are at varying stages
of clinical development and one of them already has a Over the past 2 years placebo controlled clinical stud-
ies have been published and these have confirmed pari-product license in some countries.
calcitol as an effective treatment for hyperparathyroid-
22-Oxacalcitriol ism in these patients. The studies have shown good
suppression of PTH concentrations with apparently re-22-Oxacalcitriol (OCT), first described in the late
duced tendency to increase calcium or phosphate [28].1980s, was subsequently shown experimentally to exhibit
These studies were, however, placebo controlled andprofound suppression of bovine parathyroid cells in vitro,
there are as yet no full publications in relation to thewith little or no calcemia in intact and uremic rats. Para-
comparative studies (paricalcitol vs. calcitriol) that havethyroid suppressing potency was similar to that of calci-
been completed recently. However, initial reports oftriol whereas calcitriol at equivalent doses resulted in
these are suggesting that both paricalcitol and calcitriolprofound hypercalcemia [24]. Further studies in uremic
dogs yielded broadly similar results. Unfortunately it is suppress PTH with equal efficacy, although the suppres-
clear from early clinical studies that, despite the very sion by paricalcitol at the doses used was somewhat
promising experimental profile, OCT is certainly not de- brisker. Calcemic episodes appear to have been broadly
void of calcemic effects in dialysis patients. Thus in a similar in the two groups. Thus the comparative studies
large study conducted in Japan, PTH suppression was undertaken so far appear likely to indicate that paricalci-
effective and dose dependent, but substantial numbers tol confers no important clinical benefit over calcitriol,
of patients experienced hypercalcemic episodes [25]. No at least when used according to these early protocols. It
comparative studies with calcitriol or alfacalcidol have is possible, however, that the more rapid PTH reduction
yet been undertaken and so, although it is clear that OCT in the paricalcitol-treated patients is indicative of an ex-
is effective in the context of renal hyperparathyroidism, cessively large dose of this agent having been chosen and
it is not yet clear whether OCT has any therapeutic that, with suitable modification to dosing, hypercalcemic
advantages over current standard therapy. episodes could be reduced significantly. Further studies
will be needed to clarify this point.
Paricalcitol
1a-Hydroxyvitamin D2Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) has been
developed following initial indications of a reduced ten- This compound, generic name doxercalciferol, is the vita-
min D2 equivalent of alfacalcidol. It has been widely as-dency to raise calcium and phosphorus in experimental
animals. Paricalcitol was found to suppress PTH in vitro sumed that the metabolism of alfacalcidol and 1a-hydroxy-
vitamin D2, which are, respectively, the cholecalciferoland in vivo in a dose dependent fashion and, at relevant
doses, to be essentially devoid of calcemic and phospha- and ergocalciferol derivatives of parent vitamin D, would
lead to the formation of similar quantities of biologicallytemic actions [26]. Paricalcitol also exhibited other ac-
tions expected of a vitamin D-like compound, inhibition equivalent 1,25-dihydroxyvitamin D metabolites. This now
appears not to be the case. Alfacalcidol (1a-OH D3) isof PTH gene transcription and of parathyroid cell mitotic
activity [27]. Many of the early experimental studies were 25-hydroxylated in the liver to form calcitriol, the natural
hormonal form of vitamin D3. In contrast 1a-OH D2 isconducted with calcitriol as the comparitor, and these
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ney Int 20:375–385, 1981droxyvitamin D2 metabolite raises the possibility of qual-
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development of parathyroid hyperplasia and secondary hyperpara-fication of new vitamin D regimes and new vitamin D
thyroidism in rats with renal failure. Am J Kidney Dis 28:596–602,metabolites as therapies in patients with renal osteodys- 1996
trophy, the clinical gain over the past 25 years has been 12. Brickman S, Coburn JW, Norman AW: Action of 1,25-dihydroxy-
cholecalciferol, a potent, kidney produced metabolite of vitaminmodest. Certainly the placebo-controlled studies of the
D in uremic man. N Engl J Med 287:891–895, 1972newer metabolites, and of the pulsed regimens of the 13. Chalmers TM, Hunter JO, Davie MW, Szaz KF, Pelc B, Kodicek
more traditional metabolites, have shown high efficacy. E: 1-alfa-hydroxycholecalciferol as a substitute for the kidney hor-
mone 1,25-dihydroxycholecalciferol in chronic renal failure. LancetThis is, nevertheless, very reminiscent of the results seen
2:696–699, 1973in the 1970s when calcitriol and alfacalcidol were first 14. Madsen S, Olgaard K, Ladefoged J: Suppressive effect of
used in patients with renal disease [12, 13]. There is an 1,25(OH)2 D3 on circulating parathyroid hormone in acute renal
failure. J Clin Endocrinol Metab 53:823–827, 1981urgent need for proper comparisons with current best
15. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martintherapy (using alfacalcidol or calcitriol as the compari- KJ: Marked suppression of secondary hyperparathyroidism by in-
tor) to see whether any of the new metabolites are sig- travenous administration of 1,25-dihydroxycholecalciferol in ure-
mic patients. J Clin Invest 74:2136–2143, 1984nificantly better. So far the evidence that they are is
16. Brandi L, Daugaard H, Tvedegaard E, Nielsen PK, Egsmoserelatively thin, although it is to be hoped that with further C, Storm T, Olgaard K: Long term suppression of secondary
refinement of dosing regimens some of the new metabo- hyperparathyroidism by intravenous 1a-hydroxyvitamin D3 in pa-
tients on chronic hemodialysis. Am J Nephrol 12:311–318, 1992lites may prove to have a significant clinical edge. Until
17. Moe SM, Kraus MA, Gassensmith CM, Fineberg NS, Gannonthis happens, however, there appears to be little justifi- FH, Peacock M: Safety and efficacy of pulse and daily calcitriol
cation for moving away from current best therapy with in patients on CAPD. a randomised trial. Nephrol Dial Transplant
13:1234–1241, 1998alfacalcidol or calcitriol. With these tried and tested
18. Kwan JTC, Almond MK, Beer JC, Noonan K, Evans SJW, Cun-agents the choice of regimen appears to be relatively ningham J: ‘Pulse’ oral calcitriol in uraemic patients: rapid modifi-
unimportant with respect to clinical outcomes, although cation of parathyroid response to calcium. Nephrol Dial Transplant
7:829–834, 1992may be much more so with regard to convenience of
19. Martin KJ, Ballal HS, Domoto DT, Blaylock S, Weindel M:delivery and/or national reimbursement practices. Pulse oral calcitriol for the treatment of hyperparathyroidism in
patients on continuous ambulatory peritoneal dialysis: preliminary
Reprint requests to Dr. John Cunningham, Department of Nephrol- observations. Am J Kidney Dis 19:540–545, 1992
ogy, St Bartholomew’s and the Royal London School of Medicine and 20. Fischer ER, Harris DCH: Comparison of intermittent oral and
Dentistry, Whitechapel, London, E1 1BB United Kingdom. intravenous calcitriol in hemodialysis patients with secondary hy-
perparathyroidism. Clin Nephrol 40:216–220, 1993
21. Coburn JW, Frazao J: Calcitriol in the management of renalREFERENCES
osteodystrophy. Semin Dial 9:316–326, 1996
22. Brickman AS, Coburn JW, Friedman GR, Okamura WH, Massry1. Slatopolsky E, Delmez JA: Pathogenesis of secondary hyperpara-
thyroidism. Am J Kid Dis 23:229–236, 1994 SG, Norman AW: Comparison of effects of 1a-hydroxy-vitamin
D3 and 1,25-dihydroxy-vitamin D3 in man. J Clin Invest 57:1540–2. Slatopolsky E, Martin K, Hruska K: Parathyroid hormone me-
tabolism and its potential as a uremic toxin. Am J Physiol 239:F1– 1547, 1976
23. Brown A: Vitamin D analogs. Am J Kidney Dis 32:S25–S39, 1998F12, 1980
3. Cunningham J: Parathyroid pathophysiology in uremia. Nephrol 24. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Mura-
yama E, Nishii Y, Slatopolsky E: The non calcemic analogueDial Transplant 11:S106–S110, 1996
Cunningham: Optimal vitamin D regimenS-64
of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone 28. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H,
synthesis and secretion. J Clin Invest 84:728–732, 1989 Lindberg J: 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol) safely
25. Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slato- and effectively reduces the levels of intact parathyroid hormone
polsky E: Effect of 22-oxacalcitriol on hyperparathyroidism of in patients on hemodialysis. J Am Soc Nephrol 9:1427–1432, 1998
dialysis patients. Results of a preliminary study. Nephrol Dial 29. Knutson JC, Hollis BW, Levan LW, Valliere C, Gould KG,
Transplant 11:S121–S124, 1996 Bishop CW: Metabolism of 1a-hydroxyvitaminD2 to activated di-26. Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown hydroxyvitaminD2 metabolites decreases endogenous 1a,25-dihy-A, Deluca H: A new analog of calcitriol, 19-nor-1,25-(OH)2D2, droxyvitaminD3 in rats and monkeys. Endocrinology 136:4749–suppresses parathyroid hormone secretion in uremic rats in the
4753, 1995absence of hypercalcemia. Am J Kidney Dis 26:852–860, 1995
30. Tan AU, Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knut-27. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slato-
son JC, Kleinman KS, Coburn JW: Effective suppression of para-polsky E: A new analog of 19-nor-1,25-(OH)2D2, suppresses serum
thyroid hormone by 1a-hydroxyvitaminD2 in hemodialysis patientsPTH and parathyroid gland growth in uremic rats without elevation
with moderate to severe secondary hyperparathyroidism. Kidneyof intestinal vitamin D receptor content. Am J Kidney Dis 30:105–
112, 1997 Int 51:317–323, 1997
